



## Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability

Nikhila Vengala \*

Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India

\***Corresponding author:** Nikhila Vengala, M. Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India, E-mail: nikhilavengala25@gmail.com

**Received:** February 08, 2017; **Accepted:** March 16, 2017; **Published:** March 23, 2017

### Abstract

P-glycoprotein (P-gp) is a multispecific transporter which has a herbal detoxification feature. The inhibition of substrate delivery by way of P-gp can be provided through a number of parameters. P-glycoprotein (P-gp), an efflux membrane transporter, is extensively distributed at some stage in the body and is answerable for limiting mobile uptake and the distribution of xenobiotics and toxic materials. Inhibition steady is thought to be an extra massive parameter permitting smooth assessment of statistics from wonderful substrate conditions. Because of its importance in pharmacokinetics, P-glycoprotein shipping screening has been incorporated into the drug discovery procedure. P-glycoprotein (P-gp), an efflux transporter expressed in tumour and regular tissues, may also additionally appreciably affect pharmacodynamics and pharmacokinetics of the drug, compromising its pharmacological effect. Multidrug resistance (MDR) takes place due to cellular expression of P-gp in vitro and is assumed to be a clinically applicable mechanism for tumour resistance to chemotherapy.

**Keywords:** *P-glycoprotein, Multidrug resistance, ATP binding cassette, P-gp inhibitors, Bioavailability*

### Introduction

P-glycoprotein (P-gp) is a trans layer penetrability glycoprotein having a place with the ATP binding cassette (ABC) extraordinary family that abilities particularly as a supplier intervened essential fiery efflux transporter[1-4]. It is broadly distributed all through the body and has a different scope of substrates that incorporate various fundamental recuperating retailers whose bioavailability is diminished or resistance is created as a result of the protein efflux. P-gp turn out to be initially decided in 1976 for its capacity in multi-sedate resistance in many diseases; it's far over communicated in a few human tumors and is a pivotal hindrance to accomplishment in many malignancies cure. Because of its part in medication digestion, P-gp has far reaching clinical importance as it impacts the ingestion, appropriation and discharge of anticancer pills. A few regular items from verdure and marine assets had been accounted for his or her P-gp inhibitory development and along these lines filling in as limit chemo preventives when co-controlled with hostile to malignancy operators. A few flavonoids had been articulated to manifest P-gp hindrance[5-8]. These P-gp inhibitors from common assets may also go about as limit enhancers of bioavailability of various anticancer containers by utilizing keeping the multi-medicate resistance, diminishing the intense measurement of anticancer pills and their related reactions.

**Citation:** Vengala N. Antioxidant Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability. Biochem Mol Biol Lett. 2017; 3(2):124.

© 2017 Trade Science Inc.

One of the most important defense mechanisms of ectoparasites in opposition to chemotherapeutic or xenobiotic dealers is associated with the ATP binding cassette (ABC) transporter own family. The ABC transporters were related to multidrug resistance (MDR) in one of a kind organisms. ABC proteins are able to recognize distinctive chemical substrates and to govern their delivery on a mobile stage. Through this, the ABC proteins have a pivotal role in blocking off excessive concentrations neurotoxins, which intend to go into the worried gadget of parasitic invertebrates. P-gp is a surprisingly conserved membrane sure protein in eukaryotes and prokaryotes, and it features as an ATP-structured efflux pump, reducing the attention of drugs within the cells and conferring resistance. In mammals, P-gp has been stated as one of the fundamental boundaries towards the doorway of medication from the blood flow into the nervous system [9-14].

In order to promote awareness among the people, physicians and research experts unite to form a society or an organization. The main aim of these societies is to counsel and bring awareness among the people suffering from cardiac disorders and cancer and also among healthy personnel [15-25]. ACRO India is one of the independent, non-profit organization which promotes the quality of research related to bioequivalence studies. The Nigerian Society of Biochemistry and Molecular Biology encourages researchers within the discipline of biochemistry and molecular biology to engage in huge research that ends in pleasurable results.

Open Access literature provides a source for the information and current researches worldwide. Clinical Pharmacology and Biopharmaceutics, an open access journal is informative regarding the science and technology of pharmacology and bio pharmaceutics. It deals with the study of chemical and physical properties of pharmaceuticals, their components and their activities in living organisms. Conferences like 3rd World Congress on Pharmacology August 08-10, 2016 Birmingham, UK, a presentation by Zeting Yuan on “Reversal of P-glycoprotein-mediated multidrug resistance by Cinobufagin” explains about P-gp mediated multidrug resistance. Editor Abdelwahab Omri obtained his PhD from University of Montréal whose key research interest is on effect of P-glycoprotein mediated MDR in liposomal drug delivery system[26-32].

Journal of Bioequivalence & Bioavailability is a scholarly journal that encompasses a wide range of current research on FDA Bioequivalence, Bioequivalence antipsychotics, Bioequivalence anticancer, Bioequivalence antidiuretics, Bioequivalence antipsychotics, bioavailability and bioequivalence Studies, Biosimilars, Advances in Bioavailability and offers a promising platform for the authors to make their valuable contributions towards the journal. These journals provides information through online open access and thereby helps in improving the citations for authors and attaining good journal impact factors [33,34].

## **P-GP and multidrug resistance**

The failure of cancer remedy can be attributed to a variety of various pharmacological and scientific reasons; however one important cause of the remedy failure is Multidrug Resistance (MDR) to chemotherapeutics. MDR mechanisms can bring about resistance to a number of structurally and functionally unrelated chemotherapeutic agents[35-43]. The MDR behavior is mainly related to the interest of trans membrane efflux pumps inclusive of P-glycoprotein 1 (P-gp/ABCB1), breast cancers resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 1 (MRP1/ABCC1), which are members of ATP-Binding Cassette transporter own family. P-gp, also known as multidrug resistance protein 1 (MDR1), is a nicely-studied glycoprotein that established its function as a transporter of hydrophobic pills, lipids, steroids and metabolic merchandise[44-56].

Apart from its role in multidrug resistance, P-gp has a profound function in pharmacokinetics, affecting drug absorption, distribution and excretion. It is observed in high amounts on the apical surface of epithelial cells lining the colon and small gut and in hepatocytes, pancreas ductules [57-60], proximal tubules in kidneys and the adrenal gland[61,62]. P-gp

is also recognized to play a main role in transporting compounds out of the brain in the blood brain barrier. Within the BBB, most effective certainly lipophilic compounds can diffuse throughout the endothelial cells and input the brain. But, an excessive share of P-gp that surrounds this place of the brain prevents their accumulation by means of distributing substrates returned into the blood circulate [63-69]. Inside the gastrointestinal tract and in hepatocytes, P-gp is chargeable for the efflux of medication again into lumen/bile, therefore lowering the bioavailability of substrate pills. Further, in kidneys, P-gp is placed more often than not in glomerular mesangium cells and the apical membrane of proximal tubule epithelia and plays a good sized function within the tubular secretion of organic cations [70-78].

### **P-glycoprotein mediated inhibition**

The clinical relevance of P-gp no longer best in multi-drug resistance to cancer and CNS sicknesses but additionally inside the modification of the pharmacokinetics of many tablets has sparked enormous hobby in the development of P-gp modulators so as to conquer P-gp mediated efflux delivery [79-102]. The recognition that P-gp is responsible for multi-drug resistance in most cancers and different illnesses led to applications accomplished for the invention and improvement of P-gp inhibitors in order to triumph over that functional barrier and permit drug penetration into the target tissue.

Three generations of P-gp inhibitors had been advanced over the past many years. The first-generation of P-gp inhibitors had been determined by means of investigating capsules already used in clinical practice that correctly blocked the function of P-gp In vitro and protected verapamil, cyclosporine A, anti-estrogens and anti-hypertensive analogues of quinine. But, due to their low and non-selective affinity for P-gp [103-115], excessive doses of those first-generation inhibitors were had to inhibit P-gp In vivo ensuing in clinically considerable toxicity profiles An on-going and relentless search to discover more effective and safe P-gp inhibitors stays these days no longer best for improving cancer and important apprehensive gadget -diseases remedy however also to improve the pharmacokinetic houses of several drugs [116-125]. The expertise that P-gp is strongly involved in drug kinetics caused the recognition of essential scientific drug-drug interactions with consequent impact at the disposition, dosing routine, efficacy and safety of diverse drugs and herbal dietary supplements [126-143].

### **Conclusion**

P-gp over-expression has been discovered in numerous diseases inflicting MDR to chemotherapeutics used for the treatment of tumors and CNS diseases because of the active shipping of the drugs out of the cells. Moreover, P-gp has also been proven to be an critical drug efflux transporter in intestine, liver, kidney, brain and other epithelial tissues. It is consequently documented to compromise the improvement of latest capsules with obvious successful pharmacokinetic traits and to be concerned in pharmacokinetic clinically enormous drug interactions [144,145]. Since presently P-gp is one of the most nicely understood drug efflux transporters with recognize to its regulation, tissue expression, substrate specificity and modulation of its function, it's miles critical to assess the ability of a compound to interact with P-gp.

### **References**

1. Sharifi M, Raevsky AV, Ghafourian T. Effect of Molecular Structure, Substrate and Docking Scores on the Prediction of the Inhibition Constants of P-glycoprotein Inhibitors. *J Drug Metab Toxicol.* 2016; 7:217.
2. Gupta P. P-Glycoprotein Inhibitors from Natural Sources as Chemopreventives. *Nat Prod Chem Res.* 2016; 4:e116.
3. Naruhashi K, Kamino A, Ochi E, et al. Transport Mechanism of Intestinal Absorption of  $\mu$  Opioid Receptor Agonists and Contribution of P-Glycoprotein in Rats and Human Intestinal Epithelial Caco-2. *Clin Pharmacol Biopharm.* 2016; 5:154.

4. Bedada SK, Yakkanti SA, Neerati P. Resveratrol Enhances the Bioavailability of Fexofenadine in Healthy Human Male Volunteers: Involvement of P-Glycoprotein Inhibition. *J Bioequiv Availab*. 2014; 6:158-163.
5. Valenzuela-Muñoz V, Nuñez-Acuña G, Gallardo-Escárate C. Molecular Characterization and Transcription Analysis of P-Glycoprotein Gene from the Salmon Louse *Caligus rogercresseyi*. *J Aquac Res Development*. 2014; 5:236.
6. Neerati P, Sudhakar YA, Kanwar JR. Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous Colon Perfusion Rat Model. *J Cancer Sci Ther*. 2013; 5:313-319.
7. Fortuna A, Alves G, Falcão A. In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol. *J Bioequiv Availab*. 2011; S2.
8. Karthikeyan R, Mohamed S, Sridhar V, et al. Support Vector Machine Classifier for Predicting Drug Binding to P-glycoprotein. *J Proteomics Bioinform*. 2009; 2: 193-201.
9. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur J Pharm Sci*. 2000; 11: 265-283.
10. Malmo J, Sandvig A, Varum KM, et al. Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach. *PLoS One*. 2013; 8: e54182.
11. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu Rev Pharmacol Toxicol*. 1999; 39: 361-398.
12. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? *Trends Biochem Sci*. 1992; 17: 18-21.
13. Aller S, Yu J, Ward A, et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. *Science*. 2009; 323: 1718-1722.
14. Lu L, Leonessa F, Clarke R, et al. Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase. *Mol Pharmacol*. 2001; 59: 62-68.
15. Martin C, Berridge G, Higgins CF, et al. Communication between multiple drug binding sites on P-glycoprotein. *Mol Pharmacol*. 2000; 58: 624-632.
16. Maki N, Moitra K, Ghosh P, et al. Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates. *J Biol Chem*. 2006; 281: 10769-10777.
17. Ekins S, Kim RB, Leake BF, et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. *Mol Pharmacol*. 2002; 61: 964-973.
18. Cheng Y, Prusoff WH. Relationship between the inhibition constant ( $K_i$ ) and the concentration of inhibitor which causes 50 percent inhibition ( $I_{50}$ ) of an enzymatic reaction. *Biochem Pharmacol*. 1973; 22: 3099-3108.
19. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. *Drug Metab Dispos*. 2000; 28: 655-660.
20. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Potent Cyclopropyldibenzosuberane Modulator, LY335979. *Cancer Res*. 1996; 56: 4171-4179.
21. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. *Clin Pharmacokinet*. 2007; 46: 1039-1049.

22. Ekins S, Kim RB, Leake BF, et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. *Mol Pharmacol*. 2002; 61: 974-981.
23. Eriksson UG, Dorani H, Karlsson J, et al. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. *Drug Metab Dispos*. 2006; 34: 775-782.
24. Kakumoto M, Takara K, Sakaeda T, et al. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. *Biol Pharm Bull*. 2002; 25: 1604-1607.
25. Katoh M, Nakajima M, Yamazaki H, et al. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. *Eur J Pharm Sci*. 2001; 12: 505-513.
26. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. *Eur J Pharm Sci*. 2006; 27: 543-554.
27. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J Clin Invest*. 1996; 97: 2517-2524.
28. Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. *Clin Pharmacol Ther*. 2000; 68: 231-237.
29. Wandel C, Kim R, Wood M, et al. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. *Anesthesiology*. 2002; 96: 913-920.
30. Zhang Y, Guo X, Lin ET, et al. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. *Drug Metab Dispos*. 1998; 26: 360-366.
31. Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. *J Pharmacol Exp Ther*. 2001; 299: 164-170.
32. Quan F, Pan C, Ma Q, et al. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. *Biomed Pharmacother*. 2008; 62: 622-629.
33. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. *Clin Pharmacol Ther*. 2005; 77: 170-177.
34. Yamada S, Yasui-Furukori N, Akamine Y, et al. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. *Ther Drug Monit*. 2009; 31: 764-768.
35. Shimizu M, Uno T, Sugawara K, et al. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. *Br J Clin Pharmacol*. 2006; 61: 538-544.
36. Uno T, Shimizu M, Sugawara K, et al. Lack of dose dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. *Drug Metab Dispos*. 2006; 34: 1875-1879.
37. Pohl P, Klafke G, Júnior JR, et al. ABC Transporters as a Multidrug Detoxification Mechanism in *Rhipicephalus* (*Boophilus*) *Microplus*. *Parasitol Res*. 2012; 111: 2345-2351.
38. Juranka PF, Zastawny RL, Ling V. P-Glycoprotein: Multidrug-Resistance and a Superfamily of Membrane-Associated Transport Proteins. *FASEB J*. 1989; 3: 2583-2592.
39. Pouliot Jf, L'Heureux F, Liu Z, et al. Reversal of P-Glycoprotein-Associated Multidrug Resistance by Ivermectin. *Biochem Pharmacol*. 1997; 53: 17-25.
40. Xu M, Molento M, Blackhall W, et al. Ivermectin Resistance in Nematodes May Be Caused by Alteration of P-Glycoprotein Homolog. *Mol Biochem Parasitol*. 1998; 91: 327-335.

41. Hung LW, Wang IX, Nikaido K, et al. Crystal Structure of the ATP-Binding Subunit of an ABC Transporter. *Nature*. 1998; 396: 703-707.
42. Buss DS, Mccaffery AR, Callaghan A. Evidence for P-Glycoprotein Modification of Insecticide Toxicity in Mosquitoes of the *Culex pipiens* Complex. *Med Vet Entomol*. 2002; 16: 218-222.
43. Luckenbach T, Epel D. ABCB-And ABCC-Type Transporters Confer Multixenobiotic Resistance and Form an Environment-Tissue Barrier In Bivalve Gills. *Am J Physiol Regul Integr Comp Physiol*. 2008; 294: R1919-R1929.
44. Bourguinat C, Ardelli BF, Pion S, et al. P-Glycoprotein-Like Protein, A Possible Genetic Marker for Ivermectin Resistance Selection in *Onchocerca volvulus*. *Mol Biochem Parasitol*. 2008; 158: 101-111.
45. Veau C, Faivre L, Tardivel S, et al. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. *J Pharmacol Exp Ther*. 2002; 302: 742-750.
46. Linn SC, Giaccone G. MDR1/P-glycoprotein expression in colorectal cancer. *Eur J Cancer*. 1995; 31A: 1291-1294.
47. Linardi RL, Natalini CC. Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodynamic of therapeutic drugs. *Cienc Rural*. 2006; 36: 336-341.
48. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. *Pharmacol Rev*. 2008; 60: 196-209.
49. Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res*. 1995; 12: 413-420.
50. Bansal T, Mishra G, Jaggi M, et al. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. *Eur J Pharm Sci*. 2009; 36: 580-590.
51. Lü Y, Yan Y, Wang XF. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. *Chin Med J (Engl)*. 2004; 117: 1682-1686.
52. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. *Pharmacol Rev*. 2008; 60: 196-209.
53. Singh DV, Godbole MM, Misra K. A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors. *J Mol Model*. 2013; 19: 227-238.
54. Kanwar JR, Singh N, Kanwar RK. Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. *Nanomedicine (Lond)*. 2011; 6: 701-714.
55. Shukla S, Zaher H, Hartz A, et al. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. *Pharm Res*. 2009; 26: 480-487.
56. Angelini A, Iezzi M, Di Febbo C, et al. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. *Oncol Rep*. 2008; 20: 731-735.
57. Ma JD, Tsunoda SM, Bertino JS Jr, et al. Evaluation of In vivo P-glycoprotein phenotyping probes: a need for validation. *Clin Pharmacokinet*. 2010; 49: 223-237.
58. Marchetti S, Mazzanti R, Beijinen J, et al. Concise Review: Clinical Relevance of Drug-Drug and Herb-Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein). *Oncologist*. 2007; 12: 927-941.
59. Watkins P. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. *Adv Drug Deliv Rev*. 1997; 27: 161-170.
60. Kivistö K, Niemi M, Fromm M. Functional interaction of intestinal CYP3A4 and P-glycoprotein. *Fundam Clin Pharmacol*. 2004; 18: 621-626.

61. Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta*. 1976; 455: 152-162.
62. Cascorbi I. P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations. *Handb Exp Pharmacol*. 2011; 201: 261-283.
63. Nobili S, Landini I, Giglioni B, et al. Pharmacological Strategies for overcoming Multidrug Resistance. *Curr Drug Targets*. 2006; 7: 861-879.
64. del Amo EM, Heikkinen AT, Mönkkönen J. In vitro-In vivo correlation in P-glycoprotein mediated transport in intestinal absorption. *Eur J Pharm Sci*. 2009; 36: 200-211.
65. Linnet K, Ejning T. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. *Eur Neuropsychopharmacol*. 2008; 18: 157-169.
66. Yamazaki M, Neway W, Ohe T, et al. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of In vivo results. *J Pharmacol Exp Ther*. 2001; 296: 723-35.
67. Tandon V, Kapoor B, Bano G, et al. P-glycoprotein: pharmacological relevance. *Indian J Pharmacol*. 2006; 38: 13-24.
68. Bansal T, Jaggi M, Khar R, et al. Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy. *J Pharm Pharm Sci*. 2009; 12: 46-78.
69. Aller S, Ju J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poli-specific drug binding. *Science*. 2009; 323: 1718- 1722.
70. Sauna Z, Ambudkar S. About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. *Mol Cancer Ther*. 2007; 6: 13-23.
71. Varma M, Ashokraj Y, Dey C, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. *Pharmacol Res*. 2003; 48: 347-359.
72. Fung K, Gottesman M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. *Biochem Biophys Acta*. 2009; 1794: 860-871.
73. Elsinga P, Hendrikse N, Bart J, et al. PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS. *Curr Pharm Des*. 2004; 10: 1493-1506.
74. Thuerauf N, Fromm M. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. *Eur Arch Psychiatry Clin Neurosci*. 2006; 256: 281-286.
75. Goole J, Lindley D, Roth W, et al. The effects of excipients on transporter mediated absorption. *Int J Pharm*. 2010; 393: 17-31.
76. Choong E, Dobrinan M, Carrupt PA, et al. The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. *Expert Opinion Drug Metab Toxicol*. 2010; 6: 953-965.
77. Miura M, Uno T, Tateishi T, et al. Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects. *Chirality* . 2007; 19: 223-227.
78. Nikisch G, Eap C, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. *Pharmacol Res*. 2008; 58: 344-347.
79. Sakugawa T, Miura M, Hokama N, et al. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. *Br J Clin Pharmacol*. 2009; 67: 535-540.

80. McDevitt C, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? *Pharmacol Therap.* 2007; 113: 429-441.
81. Vaalburg W, Hendrikse N, Elsinga P, et al. P-glycoprotein activity and biological response. *Toxicol Appl Pharmacol.* 2005; 207: S257-S260.
82. Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. *J Clin Pathol.* 2002; 55: 332-339.
83. Bebawy M, Sze DM . Targeting P-glycoprotein for Effective Oral Anti- Cancer Chemotherapeutics *Curr Cancer Drug Targets.* 2008; 8: 47-52.
84. van Kalken C, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. *Am J Pathol.* 1992; 141: 1063-1072.
85. Huls M, Russel F, Masereeuw R. The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ Regeneration. *J Pharmacol Exp Ther.* 2009; 328: 3-9.
86. Canaparo R, Finnström N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. *Clin Exp Pharmacol Physiol.* 2007; 34: 1138-1144.
87. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. *Clin Pharmacokinet.* 2003; 42: 59-98.
88. Zhang Y, Benet L. The gut as a barrier to drug absorption: combined role of cytochrome P4503A and P-glycoprotein. *Clin Pharmacokinet.* 2001; 40: 159-168.
89. Waterbeemd H, Gifford E. Admet in Silico Modelling: Towards Prediction Paradise? *Nat Rev Drug Discov.* 2003; 2: 192-204.
90. Waterbeemd H, Smith D, Beaumont K, et al. Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics. *J Med Chem.* 2001; 44: 1313-1333.
91. Shugarts S, Benet L. The role of transporters in pharmacokinetics of orally administered drugs. *Pharm Res.* 2009; 26: 2039-2054.
92. Tellingen O. The importance of drug-transporting P-glycoproteins in toxicology. *Toxicol Lett.* 2001; 120: 31-41.
93. Löscher W, Potschka H. Blood-Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene Family. *NeuroRx.* 2005; 2: 86-98.
94. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. *Prog Neurobiol.* 2005; 76: 22-76.
95. Miller D. Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. *Trends Pharmacol Sci.* 2010; 31: 246-254.
96. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: A novel therapeutic approach. *Pharmacol Ther.* 2010; 125: 118-127.
97. Urquhart B, Kim R. Blood-brain barrier transporters and response to CNS-active drugs. *Eur J Clin Pharmacol.* 2009; 65: 1063-1070.
98. Kwan P, Arzimanoglou A, Berg A, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia.* 2010; 51: 1069- 1077.
99. Schmidt D, Löscher W. Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms. *Epilepsia.* 2005; 46: 858-877.

- 100.von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. *Clin Pharmacol Ther.* 2004; 75: 172-183.
- 101.Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. *Pharm Res.* 2004; 21: 719-735.
- 102.Faber KN, Müller M, Jansen PL. Drug transport proteins in the liver. *Adv Drug Deliv Rev.* 2003; 55: 107-124.
- 103.Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. *Eur J Pharm Sci.* 2004; 21: 25-51.
- 104.Kusuhara H, Sugiyama Y. In vitro-In vivo extrapolation of transporter-mediated clearance in the liver and kidney. *Drug Metab Pharmacokinet.* 2009; 24: 37-52.
- 105.Perri D, Ito S, Rowsell V, Shear NH. The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates. *Can J Clin Pharmacol.* 2003; 10: 17-23.
- 106.Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. *Adv Drug Deliv Rev.* 2003; 55: 53-81.
- 107.Taylor E. The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders. *Clin Pharmacokinet.* 2002; 41: 81-92.
- 108.Abraham J, Edgerly M, Wilson R, et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. *Clin Cancer Res.* 2009; 15: 3574-3582.
- 109.Colabufo NA, Contino M, Berardi F, et al. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents. *Toxicol In vitro.* 2011; 25: 222-230.
- 110.Eng KT, Berdis AJ. A novel non-natural nucleoside that influences P-glycoprotein activity and mediates drug resistance. *Biochemistry.* 2010; 49: 1640- 1648.
- 111.Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. *Expert Rev Anticancer Ther.* 2007; 7: 447-459.
- 112.Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. *Cancer Res.* 2000; 60: 2964-2972.
- 113.Holtzman C, Wiggins B, Spinler S. Role of P-glycoprotein in statin drug interactions. *Pharmacotherapy.* 2006; 26: 1601-1607.
- 114.International Transporter Consortium . Membrane transporters in drug development. *Nat Rev Drug Discov.* 2010; 9: 215-236.
- 115.Huang B, Li G, Luo J, et al. Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier. *World J Gastroenterol.* 2008; 14: 4928-4937.
- 116.Zhang J, Zhang Y, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. *AAPS J.* 2009; 11: 300-306.
- 117.Zhang L, Reynolds K, Zhao P, et al. Drug interactions evaluation: An integrated part of risk assessment of therapeutics. *Toxicol Appl Pharmacol.* 2010; 243: 134-145.
- 118.Hughes J, Rees S, Kalindjian S, et al. Principles of early drug discovery. *Br J Pharmacol.* 2011; 162: 1239-1249.
- 119.Yengi L, Leung L, Kao J. The Evolving Role of Drug Metabolism in Drug Discovery and Development. *Pharm Res.* 2007; 24: 842-858.

120. Schwab D, Fischer H, Tabatabaei A, et al. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. *J Med Chem.* 2003; 46: 1716-1725.
121. Hochman J, Yamazaki M, Ohe T, et al. Evaluation of Drug Interactions with P-Glycoprotein in Drug Discovery: In vitro Assessment of the Potential for Drug-Drug Interactions with P-Glycoprotein. *Curr Drug Metab.* 2002; 3: 257-273.
122. Zhang Y, Bachmeier C, Miller DW. In vitro and In vivo models for assessing drug efflux transporter activity. *Adv Drug Deliv Rev.* 2003; 55: 31-51.
123. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of In vitro and In vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. *Drug Metab Dispos.* 2003; 31: 815-832.
124. Keogh JP, Kunta JR. Development, validation and utility of an In vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. *Eur J Pharm Sci.* 2006; 27: 543-554.
125. Shaik N, Giri N, Pan G, et al. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. *Drug Metab Dispos.* 2007; 35: 2076-2085.
126. Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? *Pharm Res.* 2002; 19: 765-772.
127. Wandel C, Kim RB, Kajiji S, et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. *Cancer Res.* 1999; 59: 3944-3948.
128. Wang E, Casciano CN, Clement RP, et al. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. *Cancer Res.* 2001; 61: 7525-7529.
129. Ghafourian T, Barzegar-Jalali M, Dastmalchi S, et al. QSPR models for the prediction of apparent volume of distribution. *International journal of pharmaceutics.* 2006; 319: 82-97.
130. Löschmann N, Michaelis M, Rothweiler F, et al. Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs. *Transl Oncol.* 2013; 6: 685-696.
131. Dolgih E, Bryant C, Renslo AR, et al. Predicting Binding to P-Glycoprotein by Flexible Receptor Docking. *PLoS Comput Biol.* 2011; 7: e1002083.
132. Michaelis M, Rothweiler F, Nerretter T, et al. Differential Effects of the Oncogenic BRAF Inhibitor PLX4032 (Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function. *J Pharm Pharm Sci.* 2014; 17: 154-168.
133. Hill T, Lewicki P. *STATISTICS methods and applications. A comprehensive reference for science, industry and data mining*, StatSoft Inc. 2006; Tulsa, USA.
134. Kass GV. An Exploratory Technique for Investigating Large Quantities of Categorical Data. *Applied Statistics.* 1980; 29: 119-127.
135. Breiman L. Random forests. *Machine learning.* 2001; 45: 5-32.
136. Friedman JH. Multivariate Adaptive Regression Splines. *The Annals of Statistics.* 1991; 19: 1-67.
137. Wildman SA, Crippen GM. Prediction of Physicochemical Parameters by Atomic Contributions. *J Chem Inf Comput Sci.* 1999; 39: 868-873.
138. Wang RB, Kuo CL, Lien LL, et al. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. *J Clin Pharm Ther.* 2003; 28: 203-228.

- 139.Hawkins PC, Skillman AG, Nicholls A. Comparison of shape-matching and docking as virtual screening tools. *J Med Chem.* 2007; 50: 74-82.
- 140.Schulz-Gasch T, Stahl M. Scoring functions for protein–ligand interactions: a critical perspective. *Drug Discovery Today: Technologies.* 2004; Elsevier.
- 141.Lipkowitz KB, Boyd DB. *Reviews in computational chemistry*, 2002; Vol 18, Wiley-VCH, New York.
- 142.Davis AM, Teague SJ. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. Teague, *Angew. Chem Int Ed.* 1999; 38: 736-749.
- 143.Teague SJ. Implications of protein flexibility for drug discovery. *Nature Reviews: Drug Discovery.* 2003; 2: 527-541.
- 144.Loo TW, Bartlett MC, Clarke DM. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. *J biol chem.* 2003; 278: 13603-13606.
- 145.Loo TW, Bartlett MC, Clarke DM. Identification of Residues in the Drug Translocation Pathway of the Human Multidrug Resistance P-glycoprotein by Arginine Mutagenesis. *J of biol chem.* 2009; 284: 24074-24087.